Psychopharmacohazardology: Major hazards of the new generation of psychotherapeutic drugs

International Journal of Clinical Practice

Volumn 58, Issue 1, 2004, Pages 58-68

  Zetin, Mark ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

Adverse effects; Anticonvulsant; Antidepressant; Antipsychotic; Psychotropic; Tranquilizer

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; DANTROLENE; DILTIAZEM; DIURETIC AGENT; DROPERIDOL; ESKALITH CR; HALOPERIDOL; LITHIUM; LITHIUM CARBONATE; MESORIDAZINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; OXCARBAZEPINE; PIMOZIDE; QUETIAPINE; QUINIDINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VERAPAMIL; ZIPRASIDONE;

ACNE; ACUTE TOXICITY; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMENORRHEA; ANGINA PECTORIS; ANTEROGRADE AMNESIA; APLASTIC ANEMIA; AUTONOMIC DYSFUNCTION; BIPOLAR DISORDER; BLEEDING; BLINDNESS; BONE MARROW SUPPRESSION; BRAIN DISEASE; BREAST TUMOR; CARDIOTOXICITY; CHOREOATHETOSIS; COGNITIVE DEFECT; COMA; CONFUSION; CONSCIOUSNESS DISORDER; CREATINE KINASE BLOOD LEVEL; DIABETIC KETOACIDOSIS; DIARRHEA; DIZZINESS; DRUG ACCUMULATION; DRUG ALCOHOL INTERACTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECG ABNORMALITY; EJACULATION DISORDER; ENDOCRINE DISEASE; EOSINOPHILIA; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FALLING; FATIGUE; FEMALE INFERTILITY; FEVER; FLU LIKE SYNDROME; GALACTORRHEA; GLOMERULOSCLEROSIS; GOITER; GYNECOMASTIA; HAIR LOSS; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PALPITATION; HEMORRHAGIC PANCREATITIS; HIRSUTISM; HUMAN; HYPERAMMONEMIA; HYPERANDROGENISM; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; HYPOTHYROIDISM; INSULIN RESISTANCE; IRRITABILITY; KIDNEY CONCENTRATING CAPACITY; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY TUBULE NECROSIS; LETHARGY; LEUKOCYTOSIS; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FAILURE; LUNG EMBOLISM; MAJOR DEPRESSION; MANIA; MATURITY ONSET DIABETES MELLITUS; MENSTRUAL IRREGULARITY; MENTAL DEFICIENCY; MENTAL DISEASE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MYOCARDITIS; NAUSEA; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; OBESITY; ORGASM DISORDER; OSTEOLYSIS; OVARY POLYCYSTIC DISEASE; POLYDIPSIA; POLYNEUROPATHY; POLYURIA; PRESCRIPTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RESPIRATION DEPRESSION; RETINITIS PIGMENTOSA; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SINUS TACHYCARDIA; SLURRED SPEECH; STEVENS JOHNSON SYNDROME; SUDDEN DEATH; SYNCOPE; TARDIVE DYSKINESIA; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA; THYROID DISEASE; TREMOR; VEIN THROMBOSIS; VOMITING; VON WILLEBRAND DISEASE; WEIGHT GAIN;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; RISK FACTORS;

EID: 1342283936     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.0088.x     Document Type: Review

References (97)

1. Crimmins EM, Saito Y. Trends in healthy life expectancy in the United States, 1970-1990: gender, racial, and educational differences. Soc Sci Med 2001; 52 (11): 1629-41.
2. Grover SA, Gray-Donald K, Joseph L, et al. Life expectancy following dietary modification or smoking cessation. Estimating the benefits of a prudent lifestyle. Arch Intern Med 1994; 154 (15): 1697-704.
3. Oberman A. Principles of preventive health care. In: L G, JC B, Eds. Cecil textbook of medicine, 21st edn. Philadelphia: WB Saunders, 2000: 26-8.
4. Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001; 15 (2): 127-35.
5. Meltzer HY. Suicide and schizophrenia: clozapine and the Inter-SePT study. International Clozaril/Leponex Suicide Prevention Trial. J Clin Psychiatry 1999; 60 (Suppl. 12): 47-50.
6. Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatry Serv 1998; 49 (8): 1029-33.
7. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998; 155 (8): 1113-6.
8. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 2001; 72 (4): 325-36.
9. Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am 2000; 18 (2): 317-25.
10. Sachdev PS. The current status of tardive dyskinesia. Aust N Z J Psychiatry 2000; 34 (3): 355-69.
11. Keck Jr PE et al. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000; 61 (Suppl. 4): 33-8.
12. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000; 61 (Suppl. 4): 21-6.
13. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000; 61 (Suppl. 4): 15-20.
14. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61 (Suppl. 3): 16-21.
15. Janicak PG et al. Principles and practice of psychopharmacotherapy, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2001.
16. Soares KV, McGrath JJ. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001; (1): CD000206.
17. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2000; (2): CD000209.
18. Soares KV, McGrath JJ. Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2000; 2: CD000206.
19. Soares KV, McGrath JJ. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2000; (2): CD000204.
20. Soares KV, McGrath JJ, Deeks JJ. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001; (2): CD000203.
21. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 16 (2): 77-89.
22. Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. J Clin Psychiatry 2001; 62 (Suppl. 27): 10-4; 40-1 [discussion].
23. Henderson DC, Ettinger ER. Schizophrenia and diabetes. Int Rev Neurobiol 2002; 51: 481-501.
24. Koro CE et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325: 243.
25. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002; 63 (9): 758-62.
26. Ananth J et al. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002; 71 (5): 244-54.
27. Nissen D. Mosby's drug consult 2002. St. Louis: Elsevier Science, 2002.
28. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62 (11): 1649-71.
29. Glassman AH, Bigger Jr JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158 (11): 1774-82.
30. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry 2001; 179: 63-6.
31. Hagg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 2002; 16 (11): 765-76.
32. Hagg S et al. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001; 21 (4): 382-8.
33. Killian JG et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841-5.
34. Baldessarini RJ, Tondo L, Hennen J. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Ann N Y Acad Sci 2001; 932: 24-38; 39-43 [discussion].
35. Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000; 61 (Suppl. 9): 97-104.
36. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104 (3): 163-72.
37. Coppen A. Lithium in unipolar depression and the prevention of suicide. J Clin Psychiatry 2000; 61 (Suppl. 9): 52-6.
38. Oakley PW, Whyte IM, Carter GL. Lithium toxicity: an iatrogenic problem in susceptible individuals. Aust N Z J Psychiatry 2001; 35 (6): 833-40.
39. Bendz H, Aurell M, Lanke J. A historical cohort study of kidney damage in long-term lithium patients: continued surveillance needed. Eur Psychiatry 2001; 16 (4): 199-206.
40. Gitlin M. Lithium and the kidney: an updated review. Drug Saf 1999; 20 (3): 231-43.
41. Bocchetta A et al. Ten-year follow-up of thyroid function in lithium patients. J Clin Psychopharmacol 2001; 21 (6): 594-8.
42. Henry C. Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. J Psychiatry Neurosci 2002; 27 (2): 104-7.
43. Krahenbuhl S et al. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 2000; 20 (4): 346-8.
44. Konig SA et al. Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adults. Epilepsia 1999; 40 (7): 1036-40.
45. Chapman SA, Wacksman GP, Patterson BD. Pancreatitis associated with valproic acid: a review of the literature. Pharmacotherapy 2001; 21 (12): 1549-60.
46. Pellock JM et al. Acute pancreatitis coincident with valproate use: a critical review. Epilepsia 2002; 43 (11): 1421-4.
47. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22 (1): 62-5.
48. Luef G et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002; 249 (7): 835-41.
49. Luef G et al. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res 2002; 48 (1-2): 91-102.
50. O'Donovan C et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002; 63 (4): 322-30.
51. Genton P et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001; 42 (3): 295-304.
52. Kelly BD, Hillery J. Hyponatremia during carbamazepine therapy in patients with intellectual disability. J Intellect Disabil Res 2001; 45 (2): 152-6.
53. Berbel Garcia A et al. Protease inhibitor-induced carbamazepine toxicity. Clin Neuropharmacol 2000; 23 (4): 216-8.
54. Nair DR, Morris HH. Potential fluconazole-induced carbamazepine toxicity. Ann Pharmacother 1999; 33 (7-8): 790-2.
55. Besag FM, Ng GY, Pool F. Successful re-introduction of lamotrigine after initial rash. Seizure 2000; 9 (4): 282-6.
56. Calabrese JR et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002; 63 (11): 1012-9.
57. Wong IC, Mawer GE, Sander JW. Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. Epilepsia 2001; 42 (2): 237-44.
58. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999; 33 (10): 1037-42.
59. Guberman AH et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40 (7): 985-91.
60. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998; 7 (2): 163-5.
61. Farhat G et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002; 58 (9): 1348-53.
62. Feldkamp J et al. Long-term anticonvulsant therapy leads to low bone mineral density - evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000; 108 (1): 37-43.
63. Blair-West GW et al. Lifetime suicide risk in major depression: sex and age determinants. J Affect Disord 1999; 55 (2-3): 171-8.
64. Glauser J. Tricyclic antidepressant poisoning. Cleve Clin J Med 2000; 67 (10): 704-6, 709-13, 717-9.
65. Rose JC, Unis AS. A mortality index for postmarketing surveillance of new medications. Am J Emerg Med 2000; 18 (2): 176-9.
66. Grohmann R et al. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatry 1999; 32 (1): 21-8.
67. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59 (Suppl. 15): 42-8.
68. Dalfen AK, Stewart DE. Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors? Can J Psychiatry 2001; 46 (3): 258-63.
69. Aydin N et al. Neuroleptic malignant syndrome due to citalopram overdose. Can J Psychiatry 2000; 45 (10): 941-2.
70. Pisani F et al. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002; 25 (2): 91-110.
71. Joffe RT et al. Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand 2002; 105 (6): 427-30.
72. Henry C et al. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry 2001; 62 (4): 249-55.
73. Post RM et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001; 3 (5): 259-65.
74. Azaz-Livshits T, Hershko A, Ben-Chetrit E. Paroxetine associated hepatotoxicity: a report of 3 cases and a review of the literature. Pharmacopsychiatry 2002; 35 (3): 112-5.
75. Odeh M et al. Severe hepatotoxicity with jaundice associated with paroxetine. Am J Gastroenterol 2001; 96 (8): 2494-6.
76. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998; 12 (5): 482-91.
77. Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother 2002; 36 (1): 67-71.
78. DeSilva KE et al. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001; 15 (10): 1281-5.
79. Chechani V. Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. Crit Care Med 2002; 30 (2): 473-6.
80. McDaniel WW. Serotonin syndrome: early management with cyproheptadine. Ann Pharmacother 2001; 35 (7-8): 870-3.
81. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999; 13 (1): 100-9.
82. Black K et al. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000; 25 (3): 255-61.
83. Dunner DL et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59 (7): 366-73.
84. Hesse LM et al. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001; 29 (2): 100-2.
85. Hernandez JL et al. Severe serotonin syndrome induced by mirtazapine monotherapy. Ann Pharmacother 2002; 36 (4): 641-3.
86. Hui CK et al. Mirtazapine-induced hepatotoxicity. J Clin Gastroenterol 2002; 35 (3): 270-1.
87. Carvajal GP et al. Hepatotoxicity associated with the new anti-depressants. J Clin Psychiatry 2002; 63 (2): 135-7.
88. Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 2002; 47 (4): 375-7.
89. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Artheroscler Suppl 2002; 3 (1): 35-40.
90. Thompson M, Samuels S. Rhabdomyolysis with simvastatin and nefazodone. Am J Psychiatry 2002; 159 (9): 1607.
91. Garton T. Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus 1. Transplantation 2002; 74 (5): 745.
92. Olyaei AJ et al. Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. Pharmacotherapy 1998; 18 (6): 1356-9.
93. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002; 159 (11): 1869-75.
94. Ensrud KE et al. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 2002; 50 (10): 1629-37.
95. Frels C et al. Iatrogenic causes of falls in hospitalised elderly patients: a case-control study. Postgrad Med J 2002; 78 (922): 487-9.
96. McGwin Jr G et al. Relations among chronic medical conditions, medications, and automobile crashes in the elderly: a population-based case-control study. Am J Epidemiol 2000; 152 (5): 424-31.
97. Rickels K et al. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine. Am J Phychiary 2000; 157 (12): 1973-9.